Chronic Myelogenous Leukemia in Chronic Phase for 16 Years: Ongoing Hematological Remission and Late Minor Cytogenetic Response under Minimal Interferon Maintenance Therapy

References

• Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM. Survival with bone marrow transplantation versus hydroxyurea or inter-feron for chronic myelogenous leukemia. Blood 1998; 91: 1810–1819, and the German CML Study Group
   PubMed Web of Science ®Google Scholar
• Cervantes F, Robertson JE, Rozman C, Baccarani M, Tura S, Gomez GA, Braun TJ, Clarkson BD, Pereira A. Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. British Journal of Haematology 1994; 87: 293–300, and the Italian Cooperative CML Study Group
   PubMed Web of Science ®Google Scholar
• Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Journal of the National Cancer Institute 1997; 89: 1616–1620
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, Guerci A, Harrousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New England Journal of Medicine 1997; 337: 223–229, for the French Chronic Myeloid Leukemia Study Group
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon alpha therapy. Annah of Internal Medicine 1995; 122: 254–261
   PubMed Web of Science ®Google Scholar
• Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised. multicentre trial of inter-feron-anl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. American Journal of Medicine 1990; 88: 1–8
   PubMed Web of Science ®Google Scholar
• Lamy TH, Dauriac C, Le Prise PY. Long-term survival in chronic granulocytic leukaemia. British Journal of Haematology 1989; 73: 219
   Web of Science ®Google Scholar
• Prischl FC, Haas OA, Lion T, Eyb R, Schwarzmeier JD. Duration of first remission as an indicator of long-term survival in chronic myelogenous leukaemia. British Journal of Haemaiology 1989; 71: 337–342
   PubMed Web of Science ®Google Scholar
• Nowell PC, Jackson L, Weiss A, Kurzrock R. Historical communication: Philadelphia-positive chronic myelogenous leukemia followed for 27 years. Cancer Genetics and Cytogenetics 1988; 34: 57–61
   PubMed Web of Science ®Google Scholar
• Najean Y, Miclea M, Tanzer J, Lessard M, Sigaux F. Chronic myelocytic leukaemia with unusual (27 years) complete remission terminating in acute undifferentiated leukaemia: a clinical and karyotypic study. Leukemia 1991; 5: 621–623
   PubMed Web of Science ®Google Scholar
• Amikam D, Hening C, Sharon R, Tatarsky I, Ben-Lshai Z. Molecular analysis of an asymptomatic Ph-positive CML patient with 27 years of prolonged remission. American Journal of Hematology 1994; 46: 358–362
   PubMed Web of Science ®Google Scholar
• Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau MM, Tantravahi R, Bloomfield CD. Prolonged subcutaneous administration of recombinant a2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993; 82: 2975–2984
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H, Kumock R, Gutterman JU. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer 1992; 69: 410–412
   PubMed Web of Science ®Google Scholar
• Shepherd PC, Richards S, Allan NC. Severe cytope-nias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia. British Journal of Haemntology 1994; 86: 92–96
   PubMed Web of Science ®Google Scholar
• Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, Talpaz M, Arlinghaus RB. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 1998; 12: 155–163
   PubMed Web of Science ®Google Scholar
• Haas OA, Schwarzmeier JD, Nacheva E, Fischer P, Paietta E. Investigations on karyotype evolution in patients with chronic myeloid leukemia. Blut 1984; 48: 33–43
   PubMedGoogle Scholar
• Fiegl M, Zojer N, Drach J. Molecular cytogenetics in cancer research and clinical oncology: hematological malignancies. Onkologie 1998; 21: 190–197
   Web of Science ®Google Scholar
• Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, Phenvani R, Rios MB, Stass SA, Kantarjian HM. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 1995; 85: 2705–2710
   PubMed Web of Science ®Google Scholar
• Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowslu TP, Silver RT, Sher DA, Wu D, LeBeau MM, Schiffer CA, Bloomfield CD. Value of molecular monitoring during the treatment of chronic myloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 1997; 15: 26–36
   PubMed Web of Science ®Google Scholar